Javascript must be enabled to continue!
Safety and Efficacy of Rifaximin in Prophylaxis of Spontaneous Bacterial Peritonitis: A Systematic Review and Meta-analysis
View through CrossRef
Aim:
The role of rifaximin in the prevention of Spontaneous Bacterial Peritonitis (SBP) is
not well studied. The aim of this meta-analysis was to evaluate the role of rifaximin in the prevention
of SBP.
Methods:
A computerized literature search for relevant clinical trials was conducted during August
2017. Data on Frequency of SBP, the success rate of prevention of SBP, mortality rate, hepatorenal
syndrome, septic shock, hepatic encephalopathy, and GIT bleeding were extracted and pooled as Risk
Ratio (RR) with their 95% Confidence Interval (CI) in a meta-analysis model. Heterogeneity was assessed
by Chi-square test.
Results:
Six studies involving 973 patients were included in the final analysis. The pooled effect estimate
showed that the rifaximin plus norfloxacin group had less incidence of SBP (RR 0.58, 95%
CI[0.37, 0.92], P=0.02) and hepatic encephalopathy (RR 0.38, 95% CI[0.17, 0.84], P=0.02) than the
norfloxacin-based regimen group. No significant difference between rifaximin and norfloxacin in
terms of frequency of SBP and success rate of primary prevention of SBP (RR 0.49, 95% CI [0.24,
1.01], P=0.05; RR1.21, 95% CI [0.95, 1.55], P=0.13, respectively).
Conclusion:
Based on our analysis, Rifaximin is a promising drug and appears to be a good alternative
to norfloxacin in the prevention of SBP.
Bentham Science Publishers Ltd.
Title: Safety and Efficacy of Rifaximin in Prophylaxis of Spontaneous Bacterial Peritonitis: A Systematic Review and Meta-analysis
Description:
Aim:
The role of rifaximin in the prevention of Spontaneous Bacterial Peritonitis (SBP) is
not well studied.
The aim of this meta-analysis was to evaluate the role of rifaximin in the prevention
of SBP.
Methods:
A computerized literature search for relevant clinical trials was conducted during August
2017.
Data on Frequency of SBP, the success rate of prevention of SBP, mortality rate, hepatorenal
syndrome, septic shock, hepatic encephalopathy, and GIT bleeding were extracted and pooled as Risk
Ratio (RR) with their 95% Confidence Interval (CI) in a meta-analysis model.
Heterogeneity was assessed
by Chi-square test.
Results:
Six studies involving 973 patients were included in the final analysis.
The pooled effect estimate
showed that the rifaximin plus norfloxacin group had less incidence of SBP (RR 0.
58, 95%
CI[0.
37, 0.
92], P=0.
02) and hepatic encephalopathy (RR 0.
38, 95% CI[0.
17, 0.
84], P=0.
02) than the
norfloxacin-based regimen group.
No significant difference between rifaximin and norfloxacin in
terms of frequency of SBP and success rate of primary prevention of SBP (RR 0.
49, 95% CI [0.
24,
1.
01], P=0.
05; RR1.
21, 95% CI [0.
95, 1.
55], P=0.
13, respectively).
Conclusion:
Based on our analysis, Rifaximin is a promising drug and appears to be a good alternative
to norfloxacin in the prevention of SBP.
Related Results
Pola Kasus dan Penatalaksanaan Peritonitis Akut di Bangsal Bedah RSUP Dr. M. Djamil Padang
Pola Kasus dan Penatalaksanaan Peritonitis Akut di Bangsal Bedah RSUP Dr. M. Djamil Padang
AbstrakPeritonitis menjadi salah satu penyebab tersering akut abdomen yang merupakan suatu kegawatan abdomen. Peritonitis biasanya disertai dengan bakterisemia atau sepsis yang dap...
MO702: Etiology and the Impact of Refractory Peritonitis on Clinical Outcomes of Patients on Peritoneal Dialysis—12 Years’ Single-Center Experience from Turkey
MO702: Etiology and the Impact of Refractory Peritonitis on Clinical Outcomes of Patients on Peritoneal Dialysis—12 Years’ Single-Center Experience from Turkey
Abstract
BACKGROUND AND AIMS
The outcomes of refractory peritonitis in peritoneal dialysis (PD) patients have been reported to b...
Evaluating the Science to Inform the Physical Activity Guidelines for Americans Midcourse Report
Evaluating the Science to Inform the Physical Activity Guidelines for Americans Midcourse Report
Abstract
The Physical Activity Guidelines for Americans (Guidelines) advises older adults to be as active as possible. Yet, despite the well documented benefits of physical activi...
Long-term rifaximin therapy as a primary prevention of hepatorenal syndrome
Long-term rifaximin therapy as a primary prevention of hepatorenal syndrome
Background
Hepatorenal syndrome (HRS) is a severe complication of liver cirrhosis, with poor survival. Rifaximin is a gut-selective broad-spectrum antibiotic.
...
Spontaneous fungal peritonitis: a rare but severe complication of liver cirrhosis
Spontaneous fungal peritonitis: a rare but severe complication of liver cirrhosis
Introduction and aim
Spontaneous bacterial peritonitis is the most common infectious complication in cirrhosis. Spontaneous fungal peritonitis is rare and remains unkno...
Safety and Efficacy of Atezolizumab in Ovarian Cancer
Safety and Efficacy of Atezolizumab in Ovarian Cancer
Abstract
Introduction
Although the efficacy of PD-L1 blockade has been evaluated in analyses that combine pharmacologically distinct antibodies, the specific efficacy and safety of...
Eradication of <i>Helicobacter pylori</i>: Are Rifaximin-Based Regimens Effective?
Eradication of <i>Helicobacter pylori</i>: Are Rifaximin-Based Regimens Effective?
Rifaximin is a non-absorbed semisynthetic rifamycin derivative with a broad spectrum of antibacterial activity including Gram-positive and Gram-negative bacteria, both aerobes and ...
Rifaximin Treatment of Collagenous Colitis: A Randomised, Double-Blind, Placebo-Controlled Trial
Rifaximin Treatment of Collagenous Colitis: A Randomised, Double-Blind, Placebo-Controlled Trial
<b><i>Introduction:</i></b> Collagenous colitis (CC) is a disabling disease primarily affecting elderly women. Sparse, well-documented treatment modalities ...

